Repeated intermittent administration of a ubiquitous proteasome inhibitor leads to restrictive cardiomyopathy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Bortezomib Plus Melphalan-Induced Cardiomyopathy Presenting as Sinus Tachycardia and Systolic Heart Failure.Cureus · 2020
   Article
2. Proteasome dysfunction in cardiomyopathies.The Journal of physiology · 2017
   Review
3. Delineation of Molecular Pathways Involved in Cardiomyopathies Caused by Troponin T Mutations.Molecular & cellular proteomics : MCP · 2016
   Article
4. Proteasomal and lysosomal protein degradation and heart disease.Journal of molecular and cellular cardiology · 2014
   Review
5. Gambogic acid moderates cardiac responses to chronic hypoxia likely by acting on the proteasome and NF-κB pathway.American journal of cardiovascular disease · 2013
   Article

Corrections and comments

• Comment on
  Primary proteasome inhibition results in cardiac dysfunction.2013

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as